Corvus Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 04 2020 - 04:05PM
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage
biopharmaceutical company, today announced that it will present at
the 2020 Wedbush PacGrow Healthcare Virtual Conference. The
presentation will be on Tuesday, August 11 from 2:55-3:25pm ET.
A webcast of the presentation will be available live and for 90
days following the event. The webcast may be accessed via the
investor relations section of the Corvus website.
About Corvus Pharmaceuticals Corvus
Pharmaceuticals is a clinical-stage biopharmaceutical company.
Corvus’ lead product candidates are ciforadenant (CPI-444), a small
molecule inhibitor of the A2A receptor, and CPI-006, a humanized
monoclonal antibody directed against CD73 that exhibits
immunomodulatory activity and activation of immune cells. These
product candidates are being studied in ongoing Phase 1b/2 and
Phase 1/1b clinical trials in patients with a wide range of
advanced solid tumors. Ciforadenant is being evaluated in a
successive expansion cohort Phase 1b/2 trial examining its activity
both as a single agent and in combination with an anti-PD-L1
antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b
clinical trial as a single agent, in combination with ciforadenant
and pembrolizumab. The Company’s third cancer clinical program,
CPI-818, an oral, small molecule drug that has been shown to
selectively inhibit ITK, is in a multicenter Phase 1/1b clinical
trial in patients with several types of T-cell lymphomas. The
Company is also evaluating CPI-006 as a treatment for COVID-19
patients. For more information, visit
www.corvuspharma.com.
INVESTOR CONTACT: Leiv Lea Chief
Financial Officer Corvus Pharmaceuticals, Inc. 650-900-4522
LLea@corvuspharma.com
MEDIA CONTACT: Sheryl Seapy W2O pure +1
213-262-9390 sseapy@purecommunications.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Mar 2023 to Mar 2024